Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non–Small Cell Lung Cancer
JCO Precision Oncology · 2025
DOI: 10.1200/po-24-00673 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Deborah Di-Xin Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Oncogenes, Genes, Tumor Suppressor. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Next-generation sequencing in non–small cell lung cancer (NSCLC) identifies somatic genomic variants (SGVs) in cancer susceptibility genes (CSGs). We hypothesized that SGVs would be associated with poorer overall survival (OS) but greater benefit with immune checkpoint inhibitors over chemotherapy. We investigated the prevalence and predictive value of SGVs, using data from OAK and POPLAR trials comparing atezolizumab with docetaxel. METHODS We curated a list of SGVs (excluding TP53 , EGFR , ALK , and ROS1 ) on the basis of CSGs associated with tumorigenesis. We classified participants as SGV mutant or wild-type using baseline plasma analyzed by the FoundationOne Liquid CDx assay. Cox regression analyses and interaction tests between SGV status and treatment were performed. RESULTS Of 762 participants, 29% harbored an SGV. The SGV mutant group had worse OS (hazard ratio [HR], 1.28, 95% CI, 1.06 to 1.54), and within each treatment arm (docetaxel: HR, 1.31; atezolizumab: HR, 1.27). In the atezolizumab arm, the SGV mutant group compared with wild-type had worse OS in the PD-L1 high (HR, 1.31 [95% CI, 0.59 to 2.91]) and low (HR, 1.38 [95% CI, 0.98 to 1.93]) subgroups. SGV with missense, splice, and nonsense mutations had significantly worse OS than wild-type in the docetaxel arm (log-rank P = .01) but not in the atezolizumab arm (log-rank P = .33). SGV status did not predict greater OS benefit with atezolizumab over docetaxel (interaction P = .67). CONCLUSION In advanced NSCLC after chemotherapy progression, plasma-detected SGVs are common, and associated with inferior OS. Plasma SGV status should be considered as a stratification factor in future trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
- St George Hospital, Kogarah, NSW, Australia.
- Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, NSW Health Pathology, Camperdown, NSW, Australia.
- Faculty of Medicine and Health and Western Sydney University School of Medicine, University of Sydney, Camperdown, NSW, Australia.
- Prince of Wales Hereditary Cancer Centre, Randwick, NSW, Australia.
- Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
ORCID-Profile: Deborah Di-Xin Zhou, Janene Dalrymple, Frank Po-Yen Lin, Wendy A Cooper, Milita Zaheed, Robert John Simes, Thomas John
Zitieren
APA
Zhou, D. D., Dalrymple, J., Klingberg, D., Lin, F. P., Lord, S. J., Cooper, W. A., Zaheed, M., Simes, R. J., John, T., & Lee, C. K. (2025). Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non–Small Cell Lung Cancer. JCO Precision Oncology. https://doi.org/10.1200/po-24-00673
Vancouver
Zhou DD, Dalrymple J, Klingberg D, Lin FP, Lord SJ, Cooper WA, et al. Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non–Small Cell Lung Cancer. JCO Precision Oncology. 2025. doi:10.1200/po-24-00673
BibTeX
@article{Zhou2025,
author = {Zhou, Deborah Di-Xin and Dalrymple, Janene and Klingberg, Danielle and Lin, Frank Po-Yen and Lord, Sarah J and Cooper, Wendy A and Zaheed, Milita and Simes, Robert John and John, Thomas and Lee, Chee Khoon},
title = {Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non–Small Cell Lung Cancer},
journal = {JCO Precision Oncology},
year = {2025},
doi = {10.1200/po-24-00673}
}
EUVIMED